Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)
ConditionPsoriasis Vulgaris
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Ghent
About this trial
Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study we aim to investigate the predictive value of early serum trough levels of brodalumab and determine the therapeutic window of brodalumab in psoriasis patients.
Eligibility criteria
Qualifiers
Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
Disqualifiers
Participants who have currently a predominant nonplaque form of psoriasis
Participants who are pregnant, nursing or planning a pregnancy
Participants who are unable or unwilling to undergo multiple venapunctures
Participants who are treated according to a different dosing schedule than standard dosing of brodalumab
Trial design
Treatments tested in this trial
- Venapuncture
- Patient questionnaires
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov